Download PDF
Semin Liver Dis 2004; 24: 9-18
DOI: 10.1055/s-2004-832923
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Use of Diagnostic Testing for Managing Hepatitis C Virus Infection

Andrea Ferreira-Gonzalez1 , Mitchell L. Shiffman2
  • 1Division of Molecular Diagnostics, Department of Pathology, Virginia Commonwealth University Medical Center, Richmond, Virginia
  • 2Department of Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, Virginia
Further Information

Publication History

Publication Date:
02 September 2004 (online)

    Permissions and Reprints

Serological and virological testing for the hepatitis C virus (HCV) is essential in the management of patients with chronic HCV infection. Recent advances in molecular virology tests and the development of a new international unit standard have greatly simplified the use and interpretation of these tests. In the absence of treatment, baseline serum HCV RNA does not change over time and does not correlate with the severity of hepatic inflammation or fibrosis on liver biopsy. In contrast, changes in serum HCV RNA level are important predictors of virological response to treatment with pegylated interferon and ribavirin.

KEYWORDS

Hepatitis C - diagnosis - polymerase chain reaction - enzyme-linked immunoabsorbent assay - branched-chain DNA assay

REFERENCES

  • 1 Choo Q L, Kuo G, Weiner A J et al.. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.  Science. 1989;  244 359-362
    CrossrefPubMedSearch in Google Scholar
  • 2 Kuo G, Choo Q L, Alter H J et al.. An assay for circulating antibodies to the major etiologic virus of human non-A, non-B hepatitis.  Science. 1989;  244 362-364
    CrossrefPubMedSearch in Google Scholar
  • 3 Alter H J, Purcell R H, Shih J W et al.. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.  N Engl J Med. 1989;  321 1494-1500
    CrossrefPubMedSearch in Google Scholar
  • 4 Gretch D R. Use and interpretation of HCV diagnostic tests in the clinical setting.  Clin Liver Dis. 1977;  1 543-557
    PubMedSearch in Google Scholar
  • 5 Zaaijer H L, Cuypers H T, Reesink H W et al.. Reliability of polymerase chain reaction for detection of hepatitis C virus.  Lancet. 1993;  341 722-724
    CrossrefPubMedSearch in Google Scholar
  • 6 Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO collaborative study group.  Vox Sang. 1999;  76 149-158
    CrossrefPubMedSearch in Google Scholar
  • 7 Simmonds P. Variability of hepatitis C virus.  Hepatology. 1995;  21 570-583
    CrossrefPubMedSearch in Google Scholar
  • 8 Fried M W, Hadziannis S. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.  Semin Liver Dis. 2004;  24(suppl 2) 47-54
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Schiff E R, de Medina M, Kahn R S. New perspectives in the diagnosis of hepatitis C.  Semin Liver Dis. 1999;  19 3-15
    PubMedSearch in Google Scholar
  • 10 Gretch D R. Diagnostic tests for hepatitis C.  Hepatology. 1997;  26(suppl) 43S-47S
    CrossrefPubMedSearch in Google Scholar
  • 11 Kao J H, Lai M Y, Hwang Y T et al.. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay: a clinicopathologic study and demonstration of the usefulness of a third-generation assay.  Dig Dis Sci. 1996;  41 161-165
    PubMedSearch in Google Scholar
  • 12 Barrera J, Prancis B, Ercilla G et al.. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA.  Vox Sang. 1995;  68 15-18
    PubMedSearch in Google Scholar
  • 13 Fried M W, Draguesku J O, Shindo M et al.. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis.  Dig Dis Sci. 1993;  38 631-636
    CrossrefPubMedSearch in Google Scholar
  • 14 Alter M J. The epidemiology of acute and chronic hepatitis C.  Clin Liver Dis. 1997;  1 559-568
    PubMedSearch in Google Scholar
  • 15 Thio C L, Nolt K R, Astemborski J et al.. Screening for hepatitis C virus in human immunodeficiency virus -infected individuals.  J Clin Microbiol. 2000;  38 575-577
    PubMedSearch in Google Scholar
  • 16 Colin C, Lanoir D, Touzet S et al.. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature.  J Viral Hepat. 2001;  8 87-95
    CrossrefPubMedSearch in Google Scholar
  • 17 Pawlotsky J M. Use and interpretation of hepatitis C virus diagnostic assays.  Clin Liver Dis. 2003;  7 127-137
    PubMedSearch in Google Scholar
  • 18 Alter H J, Tegtmeier G, Jett B et al.. The use of recombinant immunoblot assay in the interpretation of anti-hepatitis C virus reactivity among prospectively followed patients, implicated donors and random donors.  Transfusion. 1991;  31 771-776
    CrossrefPubMedSearch in Google Scholar
  • 19 Evans C, Tobler L, Polito A et al.. Comparative evaluations of supplemental hepatitis C virus antibody test systems.  Transfusion. 1992;  32 408-414
    CrossrefPubMedSearch in Google Scholar
  • 20 Bouvier-Alias M, Patel K, Dahari H et al.. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.  Hepatology. 2002;  36 211-218
    CrossrefPubMedSearch in Google Scholar
  • 21 Lagging L M, Garcia C E, Westin J et al.. Comparison of serum hepatits C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time.  J Clin Microbiol. 2002;  40 4224-4229
    CrossrefPubMedSearch in Google Scholar
  • 22 Vellion P, Payan C, Picchio G et al.. Comparative evaluation of the total hepatits C virus core antigen, branched-DNA, and Amplicor monitor assays in determining viremia for patients with chronic hepatits C during interferon plus ribavirin combination therapy.  J Clin Microbiol. 2003;  41 3212-3220
    CrossrefPubMedSearch in Google Scholar
  • 23 Sarrazin C. Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance.  J Clin Virol. 2002;  25(Suppl 3) S23-S29
    PubMedSearch in Google Scholar
  • 24 Pawlotsky J M. Molecular diagnosis of viral hepatitis.  Gastroenterology. 2002;  122 1554-1568
    PubMedSearch in Google Scholar
  • 25 Zaaijer H L, Cuypers H T, Reesink H W et al.. Reliability of polymerase chain reaction for detection of hepatitis C virus.  Lancet. 1993;  341 722-724
    CrossrefPubMedSearch in Google Scholar
  • 26 Nolte F S, Fried M W, Shiffman M L et al.. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests.  J Clin Microbiol. 2001;  39 4005-4012
    CrossrefPubMedSearch in Google Scholar
  • 27 Komurian-Pradel F, Paranhos-Baccala G, Sodoyer M et al.. Quantitation of HCV RNA using real-time PCR and fluorimetry.  J Virol Methods. 2001;  95 111-119
    CrossrefPubMedSearch in Google Scholar
  • 28 Kleiber J, Walter T, Haberhausen G et al.. Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA.  J Mol Diagn. 2000;  2 158-166
    PubMedSearch in Google Scholar
  • 29 Kawai S, Yokosuka O, Kanda T et al.. Quantification of hepatitis C virus by TaqMan PCR: comparison with HCV Amplicor Monitor assay.  J Med Virol. 1999;  58 121-126
    CrossrefPubMedSearch in Google Scholar
  • 30 Hendricks D A, Friesenhahn M, Tanimoto L et al.. Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA.  J Clin Microbiol. 2003;  41 651-656
    CrossrefPubMedSearch in Google Scholar
  • 31 Hill C S. Molecular diagnostic testing for infectious diseases using TMA technology.  Expert Rev Mol Diagn. 2001;  1 445-455
    CrossrefPubMedSearch in Google Scholar
  • 32 Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription mediated amplification in patients with complete virologic response according to polymerase chain reaction-based asays.  Hepatology. 2000;  32 818-823
    CrossrefPubMedSearch in Google Scholar
  • 33 Urdea M S, Horn T, Fultz T J et al.. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses.  Nucleic Acids Symp Ser. 1991;  24 197-200
    PubMedSearch in Google Scholar
  • 34 Pawlotsky J M, Martinot-Peignoux M, Poveda J D et al.. Quantification of hepatitis C RNA in serum by branched chain DNA-based signal amplification assays.  J Virol Methods. 1999;  79 227-235
    CrossrefPubMedSearch in Google Scholar
  • 35 Fang J WS, Chow V, Lau J NY. Virology of hepatitis C virus.  Clin Liver Dis. 1997;  1 493-514
    PubMedSearch in Google Scholar
  • 36 Stuyver L, Wyseur A, van Arnhem W et al.. Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypable samples.  Virus Res. 1995;  38 137-157
    CrossrefPubMedSearch in Google Scholar
  • 37 Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping.  J Clin Microbiol. 1996;  34 2259-2266
    PubMedSearch in Google Scholar
  • 38 Zheng X, Pang M, Chan A et al.. Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods.  J Clin Virol. 2003;  28 214-216
    CrossrefPubMedSearch in Google Scholar
  • 39 Anderson J C, Simonetti J, Fisher D G et al.. Comparison of different HCV viral load and genotyping assays.  J Clin Virol. 2003;  28 27-37
    CrossrefPubMedSearch in Google Scholar
  • 40 Nakao T, Enomoto N, Takada N, Takada A, Date T. Typing of hepatitis C virus genomes by restriction fragment length polymorphism.  J Gen Virol. 1991;  72 2105-2112
    PubMedSearch in Google Scholar
  • 41 De Cock L, Vranckx R. Serotyping and genotyping of hepatitis C virus in Belgium.  Infection. 2003;  31 92-97
    CrossrefPubMedSearch in Google Scholar
  • 42 Pawlotsky J M, Prescott L, Simmonds P et al.. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay.  J Clin Micrbiol. 1997;  35 1734-1739
    PubMedSearch in Google Scholar
  • 43 Pawlotsky J M, Bouvier-Alias M, Hezode C et al.. Standardization of hepatitis C virus RNA quantification.  Hepatology. 2000;  32 654-657
    CrossrefPubMedSearch in Google Scholar
  • 44 Shiffman M L, Ferreria-Gonzalez A, Reddy K R et al.. Comparison of three commercially available assays for HCVRNA utilizing the international unit standard: Implications for management of patients with chronic hepatitis C virus infection in clinical practice.  Am J Gastroenterol. 2003;  98 1159-1166
    CrossrefPubMedSearch in Google Scholar
  • 45 Krajden M, Ziermann R, Khan A et al.. Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay.  J Clin Microbiol. 2002;  40 2903-2907
    CrossrefPubMedSearch in Google Scholar
  • 46 Yu M L, Chuang W L, Dai C Y et al.. Clinical evaluation of the automated Cobas Amplicor HCV Monitor test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the Quantiplex HCV Version 2.0 test.  J Clin Microbiol. 2000;  38 2933-2939
    PubMedSearch in Google Scholar
  • 47 Nguyen T, Sedghi-Vaziri A, Wilkes L et al.. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection.  J Viral Hepat. 1996;  3 75-78
    PubMedSearch in Google Scholar
  • 48 Fried M W, Shiffman M L, Reddy K R et al.. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
    CrossrefPubMedSearch in Google Scholar
  • 49 Davis G L, Wong J B, McHutchison J G et al.. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.  Hepatology. 2003;  38 645-652
    PubMedSearch in Google Scholar
  • 50 Shiffman M L, Hofmann C M, Thompson E B et al.. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C.  Hepatology. 1997;  26 780-785
    PubMedSearch in Google Scholar
  • 51 Shiffman M L, Hofmann C M, Contos M J et al.. A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders.  Gastroenterology. 1999;  117 1164-1172
    CrossrefPubMedSearch in Google Scholar
  • 52 Lee S. Histological response to interferon alfa-based therapies in hepatitis C.  Semin Liver Dis. 2004;  24(suppl 2) 55-60
    Thieme ConnectPubMedSearch in Google Scholar
  • 53 Shiffman M L, Hofmann C M, Thompson E B et al.. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C.  Hepatology. 1997;  26 780-785
    PubMedSearch in Google Scholar
  • 54 Zeuzem S, Heathcote E J, Shiffman M L et al.. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.  J Hepatol. 2003;  39 106-111
    PubMedSearch in Google Scholar

Mitchell L ShiffmanM.D. 

Hepatology Section, Virginia Commonwealth University Health System

Box 980341, Richmond, VA 23298

Email: mshiffma@hsc.vcu.edu